Mark R Flory

Dr. Mark R Flory

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
FBFuqiang Ban
Fuqiang Ban
ELEric Leblanc
Eric Leblanc
ACAyse Derya Cavga
Ayse Derya Cavga
CHChia-Chi Flora Huang
Chia-Chi Flora Huang
MFMark R Flory
Mark R Flory
ACArtem Cherkasov
Artem Cherkasov
Prostate cancer patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer. Resistance can occur when mutations in the androgen receptor (AR) render anti-androgen drugs ineffective or through the expression of constitutively active splice variants lacking the androgen binding domain entirely (e.g., ARV7). In this study, we are reporting the discovery of a novel AR-NTD covalent inhibitor 1-chloro-3-[(5-([(2S)-3-chloro-2-hydroxypropyl]amino)naphthalen-1-yl)amino]propan-2-ol (VPC-220010) targeting the AR-N-terminal Domain (AR-NTD). VPC-220010 inhibits AR-mediated transcription of full length and truncated variant ARV7, downregulates AR response genes, and selectively reduces the growth of both full-length AR- and truncated AR-dependent prostate cancer cell lines. We show that VPC-220010 disrupts interactions between AR and known coactivators and coregulatory proteins, such as CHD4, FOXA1, ZMIZ1, and several SWI/SNF complex proteins. Taken together, our data suggest that VPC-220010 is a promising small molecule that can be further optimized into effective AR-NTD inhibitor for the treatment of CRPC.

26 June 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
ZBZannel Blanchard
Zannel Blanchard
CRCraig M. Rush
Craig M. Rush
SASpencer Arnesen
Spencer Arnesen
JVJeffery M. Vahrenkamp
Jeffery M. Vahrenkamp
ARAdriana C. Rodriguez
Adriana C. Rodriguez
JGJason Gertz
Jason Gertz
Activating estrogen receptor alpha (ER; also known as ESR1) mutations are present in primary endometrial and metastatic breast cancers, promoting estrogen-independent activation of the receptor. Functional characterizations in breast cancer have established unique molecular and phenotypic consequences of the receptor, yet the impact of ER mutations in endometrial cancer has not been fully explored. In this study, we used CRISPR-Cas9 to model the clinically prevalent ER-Y537S mutation and compared results with ER-D538G to discover allele-specific differences between ER mutations in endometrial cancer. We found that constitutive activity of mutant ER resulted in changes in the expression of thousands of genes, stemming from combined alterations to ER binding and chromatin accessibility. The unique gene expression programs resulted in ER-mutant cells developing increased cancer-associated phenotypes, including migration, invasion, anchorage-independent growth, and growth in vivo. To uncover potential treatment strategies, we identified ER-associated proteins via Rapid Immunoprecipitation and Mass Spectrometry of Endogenous Proteins and interrogated two candidates, CDK9 and NCOA3. Inhibition of these regulatory proteins resulted in decreased growth and migration, representing potential novel treatment strategies for ER-mutant endometrial cancer. Implications: This study provides insight into mutant ER activity in endometrial cancer and identifies potential therapies for women with ER-mutant endometrial cancer.

12 June 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
KEKazumi ECKENSTEIN
Kazumi ECKENSTEIN
BCBeyza Cengiz
Beyza Cengiz
MCMatthew E.K. Chang
Matthew E.K. Chang
JCJessie May Cartier
Jessie May Cartier
MFMark R Flory
Mark R Flory
GTGeorge V Thomas
George V Thomas
Background/Objectives: Renal cell carcinoma (RCC) exhibits distinctive metabolic vulnerabilities that may be therapeutically targeted. This study investigates how tigecycline, an FDA-approved antibiotic that inhibits mitochondrial translation, affects RCC cells and explores potential combinatorial approaches to enhance its efficacy. Methods: We employed comprehensive metabolomic profiling, subcellular proteomics, and functional assays to characterize the effects of tigecycline on RCC cell lines, patient-derived organoids, and xenograft models. The synergistic potential of tigecycline with the histone deacetylase inhibitor entinostat was evaluated using combination index analysis. Results: Tigecycline selectively inhibited mitochondrial translation in RCC cells, reducing mitochondrially-encoded proteins while sparing nuclear-encoded components, profoundly disrupting mitochondrial bioenergetics and reducing tumor growth in xenograft models. Subcellular proteomic analyses revealed that tigecycline treatment triggered a significant accumulation of multiple histone variants concurrent with cell cycle arrest. Based on this discovery, combined treatment with tigecycline and entinostat demonstrated remarkable synergism across RCC cell lines and patient-derived. Conclusions: Our findings identify a promising therapeutic opportunity by targeting the crosstalk between mitochondrial function and epigenetic homeostasis in RCC, with the potential for rapid clinical translation given the established pharmacological profiles of both agents.

Verified
Journal Article
Open access
PDF file
MCMatthew E.K. Chang
Matthew E.K. Chang
JLJane Lange
Jane Lange
JCJessie May Cartier
Jessie May Cartier
TMTravis W. Moore
Travis W. Moore
SSSophia M Soriano
Sophia M Soriano
MFMark R Flory
Mark R Flory
There is a significant unmet need for clinical reflex tests that increase the specificity of prostate-specific antigen blood testing, the longstanding but imperfect tool for prostate cancer diagnosis. Towards this endpoint, we present the results from a discovery study that identifies new prostate-specific antigen reflex markers in a large-scale patient serum cohort using differentiating technologies for deep proteomic interrogation. We detect known prostate cancer blood markers as well as novel candidates. Through bioinformatic pathway enrichment and network analysis, we reveal associations of differentially abundant proteins with cytoskeletal, metabolic, and ribosomal activities, all of which have been previously associated with prostate cancer progression. Additionally, optimized machine learning classifier analysis reveals proteomic signatures capable of detecting the disease prior to biopsy, performing on par with an accepted clinical risk calculator benchmark.

Verified
Journal Article
Open access
PDF file
CCChristopher Cheng
Christopher Cheng
PKParul Katoch
Parul Katoch
YZYong-Ping Zhong
Yong-Ping Zhong
CHClaire T. Higgins
Claire T. Higgins
MMMaria Moredock
Maria Moredock
PSPhilip R. Streeter
Philip R. Streeter
The basal cell maintains the airway’s respiratory epithelium as the putative resident stem cell. Basal cells are known to self-renew and differentiate into airway ciliated and secretory cells. However, it is not clear if every basal cell functions as a stem cell. To address functional heterogeneity amongst the basal cell population, we developed a novel monoclonal antibody, HLO1-6H5, that identifies a subset of KRT5+ (cytokeratin 5) basal cells. We used HLO1-6H5 and other known basal cell-reactive reagents to isolate viable airway subsets from primary human airway epithelium by Fluorescence Activated Cell Sorting. Isolated primary cell subsets were assessed for the stem cell capabilities of self-renewal and differentiation in the bronchosphere assay, which revealed that bipotent stem cells were, at minimum 3-fold enriched in the HLO1-6H5+ cell subset. Crosslinking-mass spectrometry identified the HLO1-6H5 target as a glycosylated TFRC/CD71 (transferrin receptor) proteoform. The HLO1-6H5 antibody provides a valuable new tool for identifying and isolating a subset of primary human airway basal cells that are substantially enriched for bipotent stem/progenitor cells and reveals TFRC as a defining surface marker for this novel cell subset.

19 July 2023
Verified
Other
Open access
PDF file
ZBZannel Blanchard
Zannel Blanchard
CRCraig M. Rush
Craig M. Rush
SASpencer Arnesen
Spencer Arnesen
JVJeffery M. Vahrenkamp
Jeffery M. Vahrenkamp
ARAdriana C. Rodriguez
Adriana C. Rodriguez
JGJason Gertz
Jason Gertz
ER-Y537S and ER-D538G mutants drive proliferative gene expression signatures in vivo